DeepPsy provides psychiatrists with software that analyzes EEG and ECG data to predict individual patient response to treatments such as SSRIs, SNRIs, rTMS, ketamine, and ECT. By generating predictive reports, the platform shortens the time to identify effective therapies and reduces treatment costs. The solution is offered to clinicians, research institutions, and pharmaceutical companies to support precision psychiatry.
Funding
$380K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Psychiatric treatment often relies on trial-and-error methods due to the complex and variable nature of mental disorders. This can lead to delays in finding effective treatments, increased costs, and prolonged suffering for patients. A lack of objective biomarkers makes it difficult for healthcare providers to predict individual responses to different psychiatric interventions.
Solution
DeepPsy offers EEG and ECG analysis as a service, providing objective insights into a patient's neurobiology to guide treatment decisions in psychiatry. Using proprietary medical software, DeepPsy extracts features from EEG and ECG data that correlate with the probability of response to various psychiatric treatments, including rTMS, psychotropic medications, and psychedelic therapies. This approach enables a more personalized and data-driven approach to treatment selection, reducing the reliance on trial and error and potentially leading to faster recovery times. The service supports clinicians, researchers, and pharmaceutical companies in optimizing treatment strategies and developing new therapies.
Target Audience
DeepPsy serves psychiatrists, psychiatric institutions, pharmaceutical companies, and research organizations seeking to implement precision psychiatry and improve treatment outcomes for patients with mental health disorders.
Features
- EEG and ECG data analysis for biomarker discovery and patient stratification
- Proprietary medical software that extracts predictive features related to treatment response
- Generation of reports with predictive information about treatment effectiveness
- Support for various psychiatric treatments, including rTMS, psychotropic medications, and psychedelic therapies
- ISO 13485 certified quality standards for medical device practices
- Data cleaning, feature extraction, and data analysis services for pharmaceutical companies and research institutions